Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 10/20 | 0.68 |
| ▸ | LOX | P28300 | 8/20 | 0.57 |
| ▸ | MAOA | P21397 | 5/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.45 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19274325 | 0.81 | LOXL2 (1.00) | LOXL2LOXMAOAKCNH2LOXL3 | |
| Hydrochloric Acid SCHEMBL19259892 | 0.80 | LOXL2 (1.00) | LOXL2LOXMAOAKCNH2LOXL3 | |
| SCHEMBL28646852 | 0.73 | LOX (0.66) | LOXL2LOXMAOAKCNH2LOXL3 | |
| SCHEMBL19274305 | 0.73 | LOX (1.00) | LOXL2LOXMAOAKCNH2LOXL3 | |
| SCHEMBL28644342 | 0.72 | LOXL2 (0.63) | LOXL2LOXMAOAKCNH2LOXL3 | |
| SCHEMBL11045136 | 0.68 | PTGS2 (0.53) | LOXL2LOXMAOAPTGS2 | |
| SCHEMBL1368722 | 0.67 | LOXL2 (0.47) | LOXL2LOXMAOAPTGS2 | |
| SCHEMBL6303182 | 0.67 | LOXL2 (0.50) | LOXL2LOXMAOAKCNH2PTGS2 | |
| SCHEMBL27765267 | 0.67 | ALOX5 (0.55) | LOXL2PTGS2 | |
| SCHEMBL3464178 | 0.67 | LOX (0.44) | LOXL2LOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3416956-A1 | METHYLAMINE DERIVATIVES AS LYSYSL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER | The Institute of Cancer Research : The Royal Cancer Hospital (GB) | 2018-12-26 | — | — | EP | disclosed |
| WO-2017141049-A1 | METHYLAMINE DERIVATIVES AS LYSYSL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2017-08-24 | — | — | WO | disclosed |